PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7:
C07D 471/20, A61K 31/55, 31/438, A61P 37/00, C07D 495/22, 487/20, 498/20, 519/00 // (C07D 471/20, 235:00, 223:00, 221:00) (C07D 495/22, 333:00, 235:00, 223:00, 221:00)

A1

(11) International Publication Number: WO 00/37470

(43) International Publication Date: 29 June 2000 (29.06.00)

International Application Number: PCT/EP99/10176

International Filing Date: 15 December 1999 (15.12.99)

Priority Data:
98204347.3 19 December 1998 (19.12.98) EP

(71) Applicant *(for all designated States except US)*: JANSSEN PHARMACEUTICA N.V. [BE/BE]; Patent Department, Turnhoutseweg 30, B–2340 Beerse (BE).

(72) Inventors; and


(75) Inventors/Applicants *(for US only)*: JANSSENS, Frans, Eduard [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B–2340 Beerse (BE). LEENAERTS, Joseph, Elisabeth [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B–2340 Beerse (BE).

(74) Agent: QUAGHEBEUR, Luc; Janssen Pharmaceutica N.V., Patent Department – ext 3547, Turnhoutseweg 30, B–2340 Beerse (BE).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: ANTIHISTAMINIC SPIRO COMPOUNDS



(I)

(57) Abstract

This invention concerns the compounds of formula (I) a prodrug, a *N*–oxide, an addition salt, a quaternary amine or a stereochemically isomeric form thereof wherein R^1 is hydrogen, C_{1-6}alkyl, halo, formyl, carboxyl, C_{1-6}alkyloxycarbonyl, C_{1-6}alkylcarbonyl, $N(R^3R^4)C(=O)$–, $N(R^3R^4)C(=O)N(R^5)$–, ethenyl substituted with carboxyl or C_{1-6}alkyloxycarbonyl, or C_{1-6}alkyl substituted with hydroxy, carboxyl, C_{1-6}alkyloxy, C_{1-6}alkyloxycarbonyl, $N(R^3R^4)C(=O)$–, C_{1-6}alkyl$C(=O)N(R^5)$–, C_{1-6}alkyl$S(=O)_2N(R^5)$– or $N(R^3R^4)C(=O)N(R^5)$– wherein each R^3 and each R^4 independently are hydrogen or C_{1-4}alkyl, and R^5 is hydrogen or hydroxy; R^2 is hydrogen, C_{1-6}alkyl, hydroxyC_{1-6}alkyl, C_{1-6}alkyloxyC_{1-6}alkyl, $N(R^3R^4)C(=O)$–, aryl or halo; n is 1 or 2; –A–B– represents a bivalent radical of formula –Y–CH=CH–, –CH=CH–Y–, or –CH=CH–CH=CH–, wherein each hydrogen atom may independently be replaced by R^6 wherein R^6 is C_{1-6}alkyl, halo, hydroxy, C_{1-6}alkyloxy, ethenyl substituted with carboxyl or C_{1-6}alkyloxycarbonyl, hydroxyC_{1-6}alkyl, formyl, carboxyl or hydroxycarbonylC_{1-6}alkyl, and each Y independently is a bivalent radical of formula –O–, –S– or $–NR^7$–, wherein R^7 is hydrogen, C_{1-6}alkyl or C_{1-6}alkylcarbonyl; Z is a bivalent radical of formula $–(CH_2)_p$–, –CH=CH–, $–CH_2–CHOH$–, $–CH_2–O$–, $–CH_2–C(=O)$, or $–CH_2–C(=NOH)$–, provided that the bivalent radicals are connected to the nitrogen of the imidazole ring via their $–CH_2$– moiety; and wherein p is 1, 2, 3 or 4; L is hydrogen; C_{1-6}alkyl; C_{2-6}alkenyl; C_{1-6}alkylcarbonyl; C_{1-6}alkyloxycarbonyl; C_{1-6}alkyl substituted with hydroxy, carboxyl, C_{1-6}alkyloxy, C_{1-6}alkyloxycarbonyl, aryl, aryloxy, cyano or R^8HN– wherein R^8 is hydrogen, C_{1-6}alkyl, C_{1-6}alkyloxycarbonyl, C_{1-6}alkylcarbonyl; or L represents a radical of formula –Alk–Y–Het^1, –Alk–NH–CO–Het^2 or –Alk–Het^3 wherein Alk represents C_{1-4}alkanediyl; Y represents O, S or NH; Het^1, Het^2 and Het^3 each represent an optionally substituted heterocycle; for use as a medicine.